annb0t
Top 20
Recce Pharmaceuticals
Highlights:
In cohort five, RECCE® 327 (R327) demonstrated good safety and tolerability in subjects intravenously dosed at 2,000mg Independent Safety Committee approves cohort six dosing at 4,000mg; an 80-fold increase from cohort one at 50mg Subjects in cohort six have been recruited and dosing is underway
SYDNEY Australia, May 23, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX:RCE, FSE:R9Q) (the Company), the company developing a new class of synthetic ant...
>>> Read more: Recce Pharmaceuticals Announces Positive Safety Data from Fifth Cohort of Phase I Clinical Trial of RECCE® 327 and Initiates Sixth Cohort at 4,000mg
Highlights:
In cohort five, RECCE® 327 (R327) demonstrated good safety and tolerability in subjects intravenously dosed at 2,000mg Independent Safety Committee approves cohort six dosing at 4,000mg; an 80-fold increase from cohort one at 50mg Subjects in cohort six have been recruited and dosing is underway
SYDNEY Australia, May 23, 2022 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd. (ASX:RCE, FSE:R9Q) (the Company), the company developing a new class of synthetic ant...
>>> Read more: Recce Pharmaceuticals Announces Positive Safety Data from Fifth Cohort of Phase I Clinical Trial of RECCE® 327 and Initiates Sixth Cohort at 4,000mg
